Curanex Pharmaceuticals Inc Common Stock (CURX)
Automate Your Wheel Strategy on CURX
With Tiblio's Option Bot, you can configure your own wheel strategy including CURX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care
Published: April 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology's most serious and underserved supportive-care markets
Read More
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters
Published: September 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced that Dominari Securities LLC, which acted as the lead underwriter for the Company's underwritten initial public offering (the “Offering” or the “IPO”), has exercised in full the over-allotment option the Company granted to the underwriters and purchased additional 562,500 shares of common stock of the Company at the IPO price of $4.00 per share.
Read More
About Curanex Pharmaceuticals Inc Common Stock (CURX)
- IPO Date 2025-08-26
- Website https://www.curanexpharma.com
- Industry Biotechnology
- CEO Jun Liu
- Employees None